drugset / Trial / NCT03395899
Pre-operative Immunotherapy Combination Strategies in Breast Cancer
Phase 2
Completed
71 enrolled
Queen Mary University of London
Asan Medical Center · collabHoffmann-La Roche · collabKliniken Essen-Mitte · collabMedSIR · collab
RandomizedParallel-groupOpen-labelOther
Summary
International, open label, window of opportunity phase II trial that aims to evaluate the effects of immunotherapy based treatment combinations in women with untreated, histologically confirmed, operable, ER+, HER2-negative breast cancer.
Timeline
- Start
- 2017-12-21
- Primary completion
- 2023-08-18
- Completion
- 2023-08-18
Publications
- Results Schmid P, Kockx M, Kim S-B et al Dynamic changes of PD-L1 and T-cell activation in ECLIPSE: A phase II study investigating preoperative immune combination strategies in untreated, operable ER+ primary breast cancer. Cancer Res February 15 2021 (81) (4 Supplement) PD14-06.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Cobimetinib | Small molecule | 60 mg | Oral |
| Subject | Ipatasertib | Small molecule | 400 mg | — |